Patents by Inventor Nu ZHANG

Nu ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240089198
    Abstract: A packet processing method and system, and a network device are disclosed, and belong to the field of network technologies. A first network device sends a first packet to a second network device through a first tunnel, and sends a second packet to a third network device through a second tunnel. The second network device forwards the first packet to the third network device through a third tunnel. The third network device processes the first packet and the second packet. The first network device is located at a first site. The second network device and the third network device are located at a second site. The first site and the second site are connected through a wide area network. Wide area network multipath transmission may be implemented in a multi-gateway scenario.
    Type: Application
    Filed: November 17, 2023
    Publication date: March 14, 2024
    Inventors: Boyuan YU, Qi YU, Penghe TANG, Yi KAI, Huanhuan ZHANG, Nu XIA
  • Patent number: 11666596
    Abstract: Provided are applications of an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a polypeptide coded by the same. A potential ORF of 96 bases (31aa-uORF) existing in the 5? UTR of the PTEN can code an oligopeptide of 31 amino acids (named PTEN-31aa) and plays an important role in the development and progression process of tumors. Provided is a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular gliomas. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: June 6, 2023
    Assignee: THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY
    Inventor: Nu Zhang
  • Patent number: 11332540
    Abstract: The invention belongs to the field of research and development of genetic engineering antibody drugs, in particular, relates to a method for treating a tumor by administering Circ-CDH1. The Circ-CDH1 is a circular RNA Circ-CDH1 nucleic acid molecule or the protein Circ-CDH1-28 KD expressed by the circular RNA Circ-CDH1 nucleic acid molecule. In particular, a monoclonal antibody Anti-Circ-CDH1 is designed against Circ-CDH1-28 KD, which can specifically detect the content of a protein encoded by endogenous circular RNA Circ-CDH1, can remarkably inhibit invasion and metastasis of cells from tumors such as glioma, breast cancer and the like, and has wide application prospects in clinical detection of tumors and invasion and metastasis treatment.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: May 17, 2022
    Assignee: THE FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY
    Inventor: Nu Zhang
  • Publication number: 20200231695
    Abstract: The invention belongs to the field of research and development of genetic engineering antibody drugs, in particular, relates to a method for treating a tumor by administering Circ-CDH1. The Circ-CDH1 is a circular RNA Circ-CDH1 nucleic acid molecule or the protein Circ-CDH1-28 KD expressed by the circular RNA Circ-CDH1 nucleic acid molecule. In particular, a monoclonal antibody Anti-Circ-CDH1 is designed against Circ-CDH1-28 KD, which can specifically detect the content of a protein encoded by endogenous circular RNA Circ-CDH1, can remarkably inhibit invasion and metastasis of cells from tumors such as glioma, breast cancer and the like, and has wide application prospects in clinical detection of tumors and invasion and metastasis treatment.
    Type: Application
    Filed: January 17, 2020
    Publication date: July 23, 2020
    Inventor: Nu ZHANG
  • Publication number: 20200179433
    Abstract: Provided are applications of an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a polypeptide coded by the same. A potential ORF of 96 bases (31aa-uORF) existing in the 5? UTR of the PTEN can code an oligopeptide of 31 amino acids (named PTEN-31aa) and plays an important role in the development and progression process of tumors. Provided is a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular gliomas. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 11, 2020
    Inventor: Nu ZHANG
  • Publication number: 20200138915
    Abstract: Provided are an upstream Open Reading Frame (uORF) of a Phosphatase and Tensin homolog (PTEN) gene and a protein coded by the uORF. A potential ORF of 138 bases (45aa-uORF) in the 5?UTR of the PTEN, coding an oligopeptide of 45 amino acids (named PTEN-45aa) plays an important role in the development and progression progress of tumors. Further provided are a new diagnostic and therapeutic method and a drug screening platform for PTEN expression regulation related diseases, in particular neuroglioma. Also provided is a polypeptide for treatment of PTEN expression regulation related diseases.
    Type: Application
    Filed: June 8, 2018
    Publication date: May 7, 2020
    Inventor: Nu ZHANG